Changes in dependence, withdrawal, and craving among adult smokers who switch to nicotine salt pod-based e-cigarettes.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

For electronic cigarettes (e-cigarettes) to be a viable substitute for combustible cigarettes, it is likely that they must be rewarding enough for regular use, indicated by factors such as craving and dependence, important aspects of reinforcement.

This study aimed to understand short-term changes in measures of nicotine dependence between groups differing by use trajectory in a switching trial, and within group changes of these measures.

Who Took Part

The study group was 6, participants.

By PubMed's age tags, the people studied were adults, both men and women.

At week 6, participants were classified by use trajectory: exclusive smokers (n = 16), exclusive e-cigarette (n = 32), or dual users (n = 66).

How the Study Was Run

The design is described as randomized.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Secondary data analysis of one arm of an e-cigarette randomized clinical trial.

San Diego, California and Kansas City, Missouri, United States.

E-cigarette, cigarette, and total nicotine dependence (cigarette + e-cigarette), use patterns, cigarette craving and nicotine withdrawal, and cotinine were assessed at baseline and week 6 using standard measures.

What Was Measured

PubMed files the paper under topics including Craving, Electronic Nicotine Delivery Systems, Nicotine, Smokers, Tobacco Products and United States.

Author keywords: Cigarette smoking, ENDS, JUUL, dual use, nicotine dependence and reinforcement value.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide) in 6, participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.